Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med. 2011;154:541 8. S9.3-5. Lv J, Ehteshami P, Sarnak MJ, et al. Effects of intensive blood pres- sure lowering on the progression of chronic kidney disease: a sys- tematic review and meta-analysis. CMAJ. 2013;185:949 57. S9.3-6. Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kid- ney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta- analysis. Ann Intern Med. 2003;139:244 52. S9.3-7. Lambers Heerspink HJ, Brantsma AH, de Zeeuw D, et al. Albuminuria assessed from first-morning-void urine samples ver- sus 24-hour urine collections as a predictor of cardiovascular mor- bidity and mortality. Am J Epidemiol. 2008;168:897 905. S9.3-8. Lambers Heerspink HJ, Gansevoort RT, Brenner BM, et al. Comparison of different measures of urinary protein excretion for prediction of renal events. J Am Soc Nephrol. 2010;21:1355 60. S9.3-9. Contreras G, Greene T, Agodoa LY, et al. Blood pressure con- trol, drug therapy, and kidney disease. Hypertension. 2005;46: 44 50. S9.3-10. Esnault VLM, Brown EA, Apetrei E, et al. The effects of amlodip- ine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, dou- ble-blind, placebo-controlled study. Clin Ther. 2008;30:482 98. S9.3-11. Marin R, Ruilope LM, Aljama P, et al. A random comparison of fosinopril and nifedipine GITS in patients with primary renal dis- ease. J Hypertens. 2001;19:1871 6. S9.3-12. Giatras I, Lau J, Levey AS. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting- Enzyme Inhibition and Progressive Renal Disease Study Group. Ann Intern Med. 1997;127:337 45. S9.3-13. Reboussin DM, Allen NB, Griswold ME, et al. 